Higher Risk of Cytomegalovirus and Aspergillus Infections in Recipients of T Cell–Depleted Unrelated Bone Marrow: Analysis of Infectious Complications in Patients Treated with T Cell Depletion Versus Immunosuppressive Therapy to Prevent Graft-versus-Host Disease

Serious infections. A, Time to developing a serious infection (severe, life-threatening, or fatal) was similar in the 2 treatment arms over the 3-year follow-up period (P = .14). B, Survival by treatment and presence of a serious bacterial infection (P = not significant). C, Probability of developing a serious bacterial bloodstream infection (severe, life-threatening, or fatal) in the first year posttransplantation was similar in the 2 treatment arms (P = .13).

CMV. A, The probability of developing a serious CMV infection (severe, life-threatening, or fatal) was higher in the TCD arm (28%) compared with the M/C arm (17%) (P = .02). B, Three-year survival in patients who developed a serious CMV infection was 26% in the TCD arm versus 43% in the M/C arm (P = .09). C, Among CMV-seropositive recipients, the likelihood of developing a serious CMV infection was higher in the TCD arm (0.53) compared with the M/C arm (0.33) (P = .04).

Aspergillosis. A, Survival by treatment and presence of a serious fungal infection. B, The likelihood of developing aspergillosis (life-threatening or fatal) by 3 years posttransplantation was greater in the TCD arm (0.16) compared with the M/C arm (0.07) (P < .01).